INTRODUCTION
Pain is a complex neurobiological phenomenon, with a diversity of neurochemical factors contributing to both peripheral and central pain-signalling mechanisms.
Antidepressant agents are often used in the treatment of pain and may bring about their benefi cial actions through a number of mechanisms. [1] Antinociceptive effects can be enhanced by blocking 5-hydroxytryptamine 1A receptors, i.e. 5-HT 1A receptors (which have a pronociceptive infl uence), similar to the antidepressant activity. [2] Antidepressants have signifi cant pharmacological actions at crucial areas and nuclei involved in this circuit, such as the locus coeruleus nucleus, the dorsal and magnus nuclei in the raphe and the dorsal horn of the spinal cord. Thus, antidepressants can facilitate the endogenous pain control system acting at this neuroanatomical level [3] resulting in an increase in nociceptive threshold. Animal studies performed with single administration of antidepressant drugs in acute pain models of pain reaction, hot-plate test, tail fl ick test and chemical test of sub chronic pain, formalin test and writhing test, confi rm that antidepressant drugs have analgesic properties.
The increased availability of Noradrenaline (NA) and 5-Hydroxytryptamine (5-HT) in the synaptic cleft is the main, but not the only possible mechanism of the analgesic action of antidepressants. Such action would result from inhibition of reuptake of these two monoamines by blockade of their specifi c transporters in the presynaptic membrane. NA and 5-HT receptors are greatly involved in regulating nociceptive sensation at different levels in nervous system. In this regard, antidepressants seem to enhance endogenous pain control and are considered to increase or maintain the activity of the descending inhibitory bulbospinal pathway, which is compromised in chronic pain conditions. [3] Bacopa monniera (syn. Herpestis monniera L.; Scrophulariaceae) is a commonly used Ayurvedic drug for mental disorders. [4] It has been reported to exert several neuropsychopharmacological actions including anxiolytic, [5] antidepressant, [4] anticonvulsive, [6] antioxidant activity and antinociceptive activity. [7] In the present study, we investigated the possible mechanism of action behind the antinociceptive action of aqueous extract of Bacopa monniera.
MATERIALS AND METHODS

Animals
Swiss albino mice of either sex weighing 20-25g, and adult Wistar rats of either sex weighing 180-250g, were used. The animals were maintained in standard laboratory conditions with food and water ad libitum, under a 12 hour light/12 hour dark cycle. The experiment was conducted between 10:00 and 17:00 hours. The experimental protocols were approved by IAEC (Institutional Animal Ethics Committee) of Bombay College of Pharmacy.
Drugs
The following drugs were obtained from the companies as gift samples: atenolol (Ariane Orgachem, Aurangabad), yohimbine hydrochloride (Manus Aktteva, Ahemdabad), cyproheptadine hydrochloride tablets (Ciplactin, Cipla) and naloxone hydrochloride injections (Nex, Neon Labs). The aqueous extract of Bacopa monniera (AEBM) was a gift sample from Ayurchem Products, Mumbai. The specifi cations of AEBM extracts were 87.20% solubility in water and 83.20% solubility in 50% v/v alcohol, 20.70% saponins as bacosides and 5.56% and 4.93%, total ash and moisture content values, respectively, as per the Brahmi extract in-house specifi cations of Ayurchem Products. AEBM was administered after reconstitution of the dried powder extract with water. All other drug substances were dissolved in saline solution.
Mechanism studies' for involvement of different receptors in analgesic activity of antidepressants Involvement of  2 and 1 adrenergic receptors in analgesic activity in Acetic acid induced writhing test in mice [8] [9] [10] [11] In acetic acid induced abdominal writhing test, injection of irritants like acetic acid into the peritoneal cavity induces pain. It produces steady and prolonged pain associated with tissue damage and also involves more movements and postural adjustments of the abdominal portion and rest of the body. The selective adrenergic receptor blockers incorporated in the study were atenolol ( 1 ) and yohimbine ( 2 ). They were selected, since yohimbine reversed the spinal component of morphine antinociception, [12] and atenolol inhibited the analgesic effects of desipramine and nortriptyline in acetic acid induced writhing test. [13] Swiss albino mice were divided into thirteen groups [ Table 1 ] of six mice each. Food and water were provided ad libitum to the animals. [7, 14, 15] Formalin test is a well known chronic pain model of chemically induced nociception. The intraplantar injection of dilute formaldehyde causes a biphasic pain related behaviour initiated by direct stimulation of nociceptors, leading to activation of C fi bres. This fi rst phase lasts for a few minutes and refl ects the neurogenic component of nociception, being reduced mainly by opoid-like drugs. It lasts only for a few minutes and is believed to be driven by primary afferent nociceptor activity . The infl ammatory component of nociceptive response (second phase) starts after a silent period of 10-15 minutes and lasts for 60 minutes, and is thought to arise from nociceptive spinal neuronal hyperactivity. It is mediated by the release of mediators such as bradykinin, histamine, sympathomimetic amines, tumor necrosis factor and interleukins. Phase 2 is inhibited by cyclooxygenase inhibitors. Drugs that act primarily as central analgesics inhibit both the phases while peripherally acting drugs inhibit only the phase 2.
Involvement of 5-HT Receptors in Analgesic Activity in Formalin Test in Rats
Wistar rats were divided into nine groups of six rats each as shown in Table 2 . Food and water were provided ad libitum to the animals.
Involvement of opioid receptor in analgesic activity
in Tail immersion test [16, 17] Tail immersion test has been developed to be selective for morphine-like compounds. Tail fl ick is a spinally mediated refl ex to nociceptive stimuli. The fast rising pain in the tail gives rise to rapid tail fl ick and rapid tail withdrawal at the lowest possible threshold. Swiss albino mice were divided into nine groups of six mice each as shown in Table 3 . Food and water were provided ad libitum to the animals.
Statistical analysis
All results are expressed as the mean ± Standard Deviation (SD). Statistical evaluation of the data was performed using one-way analysis of variance followed by Dunnett's test. The minimum level of signifi cance considered was P < 0.05.
RESULTS
As shown in Table 4 , prior to treatment with Yohimbine (1 mg/ kg) and Atenolol (1 mg/kg) fully prevented the antinociceptive effects of AEBM (120 mg/kg and 160 mg/kg). Specifi cally, whereas the control mice treated with vehicle displayed 35.50 ± 1.52 writhes, pretreatment with yohimbine increased abdominal constrictions in AEBM (120 mg/kg) -treated mice from 25.00 ± 4.00 to 34.67 ± 2.66 writhes and in AEBM One hour later, the rats were injected with 0.05 ml of 10% formalin in the dorsal surface of the right hind paw intraplantarly. The time the animal spent licking the injected paw was recorded in two phases: First 5 minutes after formalin injection (fi rst phase, neurogenic pain response) and 20-30 minutes after formalin injection (second phase, infl ammatory pain response). Involvement of opioid receptor in analgesic activity in Tail immersion test in mice is presented in Table 6 . As shown in the Table, prior treatment with Naloxone (2 mg/kg) fully prevented the antinociceptive effects of AEBM (120 mg/kg and 160 mg/ kg). At 120 minutes, the % increase in tail fl ick latency in AEBM (120 mg/kg) and AEBM (160 mg/kg) was found to be higher than the control animals. Pretreatment with naloxone (2 mg/kg) signifi cantly decreased the % increase in tail fl ick latencies from 282.35 and 107.35 with AEBM (160 mg/kg). The prevention of antinociceptive effects after pretreatment with Naloxone as observed with AEBM (160 mg/kg) was signifi cant to those observed with AEBM (80 mg/kg and 120 mg/kg).
DISCUSSION
The involvement of monoamines, mainly serotonin and noradrenaline, in the physiological control of nociception has been well established. [15] α-adrenoceptor subtypes are distributed both spinally and supraspinally. In the abdominal constriction assay, α 2 rather than α 1 -adrenoceptors appear to play an integral role in antidepressant induced antinociception. Pharmacological and autoradiographic studies have demonstrated that opioid and α 2 -adrenoceptors are co-localized within the same laminae of the dorsal horn further suggesting a possibility of an opioidadrenoceptor interaction at the spinal level. [18] In the abdominal constriction assay, since yohimbine produced a decrement in the protective action of AEBM, indicating the probable involvement of α 2 -adrenoceptors in the analgesic action of AEBM. The β-adrenergic receptors participate in the mechanism of action of antidepressants, a hypothesis that was fi rst proposed by Vetulani et al. [19] These receptors are located in areas directly related to pain pathways. [20] β-adrenergic receptors are closely related to two neural systems that are directly implicated in pain modulation, i.e. serotonergic [21] and opioid, [22] which in turn, participate in the mechanism of action of antidepressants. In the abdominal constriction assay, β 1 -receptors seems to play a role in analgesic activity since atenolol produced a decrement in the protective action of AEBM.
The neurotransmitter 5-hydroxytryptamine (5-HT) is widely accepted as an important participant in the brain and spinal inhibition of nociceptive transmission. [23] Behavioural studies have demonstrated that 5-HT is implicated in the control exerted by the brain on the nociception either by afferent fi bre hyperpolarization or through presynaptic action. The destruction of serotonergic projection affects nociception. Serotonergic defi ciency is a common factor in both mental depression and chronic pain. [24] The increasing availability of 5-HT at the synapse is reported to inhibit nociception by acting at the spinal cord, brainstem or thalamic levels. 5-HT 1 and 5-HT 2 receptors are involved in the fl uoxetine-induced antinociception in diabetic mice. [25] We studied the involvement of 5-HT receptors in analgesic activity of AEBM, by using 5-HT 2 receptor antagonist cyproheptadine. Cyproheptadine antagonizes 5-HT receptors in the Central Nervous System (CNS) and the periphery, in addition to its antihistaminic action. [26] AEBM showed an increase in the licking time in presence of cyproheptadine. The analgesic effect was found to be dose related for AEBM. The difference in licking time values in the early and late phase indicate the involvement of 5-HT receptors in analgesic activity of AEBM.
Naloxone hydrochloride and Naltrexone hydrochloride in lower dose have been reported to be effective antagonists of opioid analgesia in Acetic acid induced writhing. [27] This suggests a complex mechanism underlying the antinociceptive effect of antidepressants. Opioids reduce the sensory discriminative component of pain [28] and antidepressant produce analgesia by potentiating the pain modulating system rather than having a direct synaptic effect. [29] Opiates enhance serotonergic activity in the brain by increasing the turnover rate of serotonin, without altering overall concentration of neurotransmitter, [30] through an indirect action via inhibition of gamma-amino-butyric acid (GABA)-containing neurons in the dorsal raphe nuclei and also by increasing 5-HT turnover at the spinal cord level. [31] In the present study increase in latency was found to reduce with time for the groups administered AEBM in combination with the antagonist, thereby indicating the involvement of opioid receptors in analgesic activity. A possible explanation for antagonism displayed by naloxone is that it blocks the release of some opioid peptides which interact as agonists at both μ and δ opioid receptors to inhibit nociceptive transmission. [31] The percentage increase in latency reduced from 1 hour onwards till 3 hours. The reduction at 0.5 hours was not signifi cant. After 3 hours, the reduction remained constant at 4 and 6 hours. In the presence of opioid receptor antagonist naloxone there was a reduction in percentage protection offered by AEBM (160 mg/kg) and thereby an antagonistic effect was observed.
CONCLUSIONS
When AEBM was given in combination with atenolol (β 1 -adrenergic receptor antagonist) and with yohimbine (α 2 -adrenergic receptor antagonist), its analgesic activity was reversed indicating the involvement of β 1 -adrenergic and α 2 -adrenergic receptors in its analgesic activity. Similarly cproheptadine also reversed analgesia, thereby indicating the involvement of 5-HT receptors in analgesic activity. AEBM, when given in combination with naloxone did not increase the latency for analgesic effect. Therefore their analgesic effect is antagonized by naloxone, which indicates involvement of opioid receptors in analgesic activity.
Thus, aqueous extract of Bacopa monniera (AEBM) exhibited analgesic activity in both acute and chronic pain conditions. The results provide evidence AEBM exhibits analgesic activity through multiple pain pathways like serotonergic, noradrenergic and opioidergic systems. Further isolation and purifi cation of the crude aqueous extract may lead to compounds with potential analgesic activity.
